16 results on '"Hinkelbein, W."'
Search Results
2. DEVELOPMENT AND INTERNAL VALIDATION OF A NOMOGRAM PREDICTING BIOCHEMICAL RECURRENCE AFTER EARLY SALVAGE RADIOTHERAPY IN PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY
- Author
-
BRIGANTI , ALBERTO, Bianchi Marco, Joniau Steven, Cozzarini Cesare, Tombal Bertrand, Haustermans Karin M., Hinkelbein W., Di Muzio Nadia, Suardi Nazareno, Hein Van Poppel, MONTORSI, FRANCESCO, Wiegel Thomas, Briganti, Alberto, Bianchi, Marco, Joniau, Steven, Cozzarini, Cesare, Tombal, Bertrand, Haustermans Karin, M., Hinkelbein, W., DI MUZIO, NADIA GISELLA, Suardi, Nazareno, Hein Van, Poppel, Montorsi, Francesco, and Wiegel, Thomas
- Published
- 2013
3. Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis
- Author
-
BRIGANTI , ALBERTO, Wiegel T, Joniau S, Cozzarini C, Bianchi M, Sun M, Tombal B, Haustermans K, Budiharto T, Hinkelbein W, Di Muzio N, Karakiewicz PI, MONTORSI , FRANCESCO, Van Poppel H., Briganti, Alberto, Wiegel, T, Joniau, S, Cozzarini, C, Bianchi, M, Sun, M, Tombal, B, Haustermans, K, Budiharto, T, Hinkelbein, W, Di Muzio, N, Karakiewicz, Pi, Montorsi, Francesco, and Van Poppel, H.
- Published
- 2012
4. Treatment planning in proton therapy of ocular tumors
- Author
-
Heufelder, Jens, Cordini, D., Karle, B., Jamil, B., Stark, R., Weber, A., Moser, L., Hinkelbein, W., Joussen, A.M., and Willerding, G.
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Hintergrund: Internationaler Standard in der Bestrahlungsplanung von Augentumoren ist das Programm EYEPLAN: Aus der im Ultraschall gemessenen Augenlänge und der durch Röntgenaufnahmen bestimmten Positionen der Tantalclips wird ein kugelförmiges Augenmodell konstruiert. Die Tumorbasis [for full text, please go to the a.m. URL], 23. Jahrestagung der Retinologischen Gesellschaft
- Published
- 2010
- Full Text
- View/download PDF
5. Visible Quality - Benchmarking in Prostate Cancer Therapy
- Author
-
Schostak, M, Schrader, M, Albers, P, Beer, M, Althaus, P, Diederichs, W, Siegsmund, M, Fabricius, G, Hinkelbein, W, Miller, K, and Projektgruppe Prostatakarzinom
- Subjects
ddc: 610 - Published
- 2006
6. Shared decision-making--results from an interdisciplinary consulting service for prostate cancer
- Author
-
Schostak, M, Höcht, S, Schrader, M, Siegmann, A, Straub, B, Bathe, K, Steiner, U, Marnitz, S, Hinkelbein, W, and Miller, K
- Subjects
ddc: 610 - Published
- 2006
7. Bestrahlungsplanung in der Protonentherapie von Augentumoren
- Author
-
Heufelder, J, Cordini, D, Karle, B, Jamil, B, Stark, R, Weber, A, Moser, L, Hinkelbein, W, Joussen, AM, Willerding, G, Heufelder, J, Cordini, D, Karle, B, Jamil, B, Stark, R, Weber, A, Moser, L, Hinkelbein, W, Joussen, AM, and Willerding, G
- Published
- 2010
8. Protontherapy of ocular tumors for very young children under general anesthesia
- Author
-
Heufelder, J, Weber, A, Moser, L, Willerding, G, Brunne, B, Cordini, D, Stark, R, Hinkelbein, W, Foerster, MH, Heufelder, J, Weber, A, Moser, L, Willerding, G, Brunne, B, Cordini, D, Stark, R, Hinkelbein, W, and Foerster, MH
- Published
- 2009
9. New aspects in the diagnosis and treatment of prostate cancer
- Author
-
Miller, K. (Kurt), Wiegel, T., Hinkelbein, W. (Wolfgang), 1948, Miller, K. (Kurt), Wiegel, T., and Hinkelbein, W. (Wolfgang), 1948
- Published
- 2003
10. P 111 Screening for intraocular metastases in breast cancer patients
- Author
-
Kleineidam, M., primary, Wiegel, T., additional, Bornfeld, N., additional, Hinkelbein, W., additional, and Foerster, M.H., additional
- Published
- 1995
- Full Text
- View/download PDF
11. First results of novel study of irinotecar (CPT-11) in patients with advanced esophageal squamous cell carcinoma and adenocarcinoma
- Author
-
Muehr-Wilkenshoff, F.B., Grabowski, P., Hinkelbein, W., Ohnesorge, I., Wolf, K.J., Schulzke, J.D., and Scheruebl, H.
- Published
- 2001
- Full Text
- View/download PDF
12. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series [Figure presented]
- Author
-
Lorenzo Tosco, Giorgio Gandaglia, Shahrokh F. Shariat, Paolo Dell'Oglio, Thomas Seisen, Claudio Fiorino, Marco Moschini, Steven Joniau, Hein Van Poppel, Alberto Bossi, Gregor Goldner, Nicola Fossati, Barbara Noris Chiorda, Karin Haustermans, Francesco Montorsi, Alessandro Morlacco, Alberto Briganti, Wolfgang Hinkelbein, Stephen A. Boorjian, Detlef Bartkowiak, R. Jeffrey Karnes, Bertrand Tombal, Thomas Wiegel, Cesare Cozzarini, Fossati, N, Karnes, Rj, Boorjian, Sa, Moschini, M, Morlacco, A, Bossi, A, Seisen, T, Cozzarini, C, Fiorino, C4, Chiorda, Bn, Gandaglia, G, Dell'Oglio, P, Joniau, S, Tosco, L, Shariat, S, Goldner, G, Hinkelbein, W, Bartkowiak, D, Haustermans, K, Tombal, B, Montorsi, Francesco, Van Poppel, H, Wiegel, T, and Briganti, A.
- Subjects
Male ,Surgical margin ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Urology ,030232 urology & nephrology ,Salvage therapy ,Kaplan-Meier Estimate ,Adenocarcinoma ,Disease-Free Survival ,Time-to-Treatment ,Tertiary Care Centers ,03 medical and health sciences ,0302 clinical medicine ,Interquartile range ,Risk Factors ,Internal medicine ,Medicine ,Humans ,Watchful Waiting ,Adjuvant ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,Retrospective Studies ,Prostatectomy ,Radiotherapy ,business.industry ,Hazard ratio ,Prostatic neoplasms ,Radiation therapy ,Kallikreins ,Middle Aged ,Multivariate Analysis ,Neoplasm Grading ,Prostate-Specific Antigen ,Prostatic Neoplasms ,Radiotherapy, Adjuvant ,Salvage Therapy ,Treatment Outcome ,Retrospective cohort study ,Surgery ,Prostate-specific antigen ,030220 oncology & carcinogenesis ,business ,Prostatic neoplasm - Abstract
Background Three prospective randomised trials reported discordant findings regarding the impact of adjuvant radiation therapy (aRT) versus observation for metastasis-free survival (MFS) and overall survival (OS) among patients with pT3N0 prostate cancer treated with radical prostatectomy (RP). None of these trials systematically included patients who underwent early salvage radiation therapy (esRT). Objective To test the hypothesis that aRT was associated with better cancer control and survival compared with observation followed by esRT. Design, setting, and participants Using a multi-institutional cohort from seven tertiary referral centres, we retrospectively identified 510 pT3pN0 patients with undetectable prostate-specific antigen (PSA) after RP between 1996 and 2009. Patients were stratified into two groups: aRT (group 1) versus observation followed by esRT in case of PSA relapse (group 2). Specifically, esRT was administered at a PSA level â¤0.5Âng/ml. Intervention We compared aRT versus observation followed by esRT. Outcome measurements and statistical analysis The evaluated outcomes were MFS and OS. Multivariable Cox regression analyses tested the association between groups (aRT vs observation followed by esRT) and oncologic outcomes. Covariates consisted of pathologic stage (pT3a vs pT3b or higher), pathologic Gleason score (â¤6, 7, or â¥8), surgical margin status (negative vs positive), and year of surgery. An interaction with groups and baseline patient risk was tested for the hypothesis that the impact of aRT versus observation followed by esRT was different by pathologic characteristics. The nonparametric curve fitting method was used to explore graphically the relationship between MFS and OS at 8 yr and baseline patient risk (derived from the multivariable analysis). Results and limitations Overall, 243 patients (48%) underwent aRT, and 267 (52%) underwent initial observation. Within the latter group, 141 patients experienced PSA relapse and received esRT. Median follow-up after RP was 94 mo (interquartile range [IQR]: 53â126) and 92 mo (IQR: 70â136), respectively (pÂ=Â0.2). MFS (92% vs 91%; pÂ=Â0.9) and OS (89% vs 92%; pÂ=Â0.9) at 8 yr after surgery were not significantly different between the two groups. These results were confirmed in multivariable analysis, in which observation followed by esRT was not associated with a significantly higher risk of distant metastasis (hazard ratio [HR]: 1.35; pÂ=Â0.4) and overall mortality (HR: 1.39; pÂ=Â0.4) compared with aRT. Using the nonparametric curve fitting method, a comparable proportion of MFS and OS at 8 yr among groups was observed regardless of pathologic cancer features (pÂ=Â0.9 and pÂ=Â0.7, respectively). Limitations consisted of the retrospective nature of the study and the relatively small size of the patient population. Conclusions At long-term follow-up, no significant differences between aRT and esRT were observed for MFS and OS. Our study, although based on retrospective data, suggests that esRT does not compromise cancer control and potentially reduces overtreatment associated with aRT. Patient summary At long-term follow-up, no significant differences in terms of distant metastasis and mortality were observed between immediate postoperative adjuvant radiation therapy (aRT) and initial observation followed by early salvage radiation therapy (esRT) in case of prostate-specific antigen relapse. Our study suggests that esRT does not compromise cancer control and potentially reduces overtreatment associated with aRT.
- Published
- 2017
13. Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in ≥PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model
- Author
-
Alberto Briganti, Claudio Fiorino, Francesco Montorsi, Gregor Goldner, Nicola Fossati, R. Jeffrey Karnes, Stephen A. Boorjian, Karin Haustermans, Riccardo Calandrino, Steven Joniau, Thomas Wiegel, Federica Palorini, Wolfgang Hinkelbein, Shahrokh F. Shariat, Cesare Cozzarini, Hein Van Poppel, Nadia Di Muzio, Sara Broggi, Fiorino, C, Broggi, S, Fossati, N, Cozzarini, C, Goldner, G, Wiegel, T, Hinkelbein, W, Karnes, Rj, Boorjian, Sa, Haustermans, K, Joniau, S, Palorini, F, Shariat, S, Montorsi, F, Van Poppel, H, Di Muzio, N, Calandrino, R, and Briganti, A
- Subjects
Male ,Radiology, Nuclear Medicine and Imaging ,Cancer Research ,medicine.medical_treatment ,Longitudinal Studie ,030218 nuclear medicine & medical imaging ,0302 clinical medicine ,Prevalence ,Longitudinal Studies ,Radiation ,Prostatectomy ,Area under the curve ,Middle Aged ,Prognosis ,Probability model ,Oncology ,Italy ,030220 oncology & carcinogenesis ,Female ,Human ,Adult ,medicine.medical_specialty ,Prognosi ,Urology ,Reproducibility of Result ,Risk Assessment ,Sensitivity and Specificity ,Disease-Free Survival ,03 medical and health sciences ,medicine ,Biomarkers, Tumor ,Humans ,Radiology, Nuclear Medicine and imaging ,Radiosensitivity ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,Models, Statistical ,Proportional hazards model ,business.industry ,Prostatic Neoplasms ,Reproducibility of Results ,Prostate-Specific Antigen ,Tumor control ,Surgery ,Radiation therapy ,Prostatic Neoplasm ,Proportional Hazards Model ,Biochemical relapse ,Radiotherapy, Adjuvant ,Neoplasm Recurrence, Local ,Radiotherapy, Conformal ,business - Abstract
Purpose To fit the individual biochemical recurrence-free survival (bRFS) data from patients treated with postprostatectomy radiation therapy (RT) with a comprehensive tumor control probability (TCP) model. Methods and Materials Considering pre-RT prostate-specific antigen (PSA) as a surrogate of the number of clonogens, bRFS may be expressed as a function of dose-per-fractionâdependent radiosensitivity (αeff), the number of clonogens for pre-RT PSA = 1 ng/mL (C), and the fraction of patients who relapse because of clonogens outside the treated volume (K), assumed to depend (linearly or exponentially) on pre-RT PSA and Gleason score (GS). Data from 894 node-negative, â¥pT2, pN0 hormone-naive patients treated with adjuvant (n=331) or salvage (n=563) intent were available: 5-year bRFS data were fitted grouping patients according to GS (7:119). Results The median follow-up time, pre-RT PSA, and dose were 72 months, 0.25 ng/mL, and 66.6 Gy (range 59.4-77.4 Gy), respectively. The best-fit values were 0.23 to 0.26 Gyâ1and 107for αeffand C for the model considering a linear dependence between K and PSA. Calibration plots showed good agreement between expected and observed incidences (slope: 0.90-0.93) and moderately high discriminative power (area under the curve [AUC]: 0.68-0.69). Cross-validation showed satisfactory results (average AUCs in the training/validation groups: 0.66-0.70). The resulting dose-effect curves strongly depend on pre-RT PSA and GS. bRFS rapidly decreases with PSA: the maximum obtainable bRFS (defined as 95% of the maximum) declined by about 2.7% and 4.5% for each increment of 0.1 ng/mL for GS 0.8-1.0 ng/mL; GS â¥7: PSA >0.3 ng/mL). Early RT should be preferred over delayed RT; the detrimental effect of PSA increase can never be fully compensated by increasing the dose, especially for patients with GS â¥7.
- Published
- 2015
14. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy
- Author
-
Pierre I. Karakiewicz, Shahrokh F. Shariat, Karin Haustermans, Francesco Montorsi, R. Jeffrey Karnes, Thomas Wiegel, Stephen A. Boorjian, Cesare Cozzarini, Wolfgang Hinkelbein, Bertrand Tombal, Steven Joniau, Maxine Sun, Hendrik Van Poppel, Alberto Briganti, Giorgio Gandaglia, Briganti, Alberto, Karnes, Rj, Joniau, S, Boorjian, Sa, Cozzarini, C, Gandaglia, G, Hinkelbein, W, Haustermans, K, Tombal, B, Shariat, S, Sun, M, Karakiewicz, Pi, Montorsi, Francesco, Van Poppel, H, and Wiegel, T.
- Subjects
Oncology ,Biochemical recurrence ,Male ,medicine.medical_specialty ,Neoplasm, Residual ,medicine.medical_treatment ,Urology ,Nomogram ,Disease-Free Survival ,Follow-Up Studie ,Prostate cancer ,Prostate ,Retrospective Studie ,Internal medicine ,medicine ,Humans ,Survival rate ,Retrospective Studies ,Neoplasm Staging ,Prostatectomy ,Salvage Therapy ,business.industry ,Proportional hazards model ,Medicine (all) ,Prostatic Neoplasms ,Middle Aged ,Prostate-Specific Antigen ,medicine.disease ,Radical prostatectomy ,Surgery ,Salvage radiotherapy ,Survival Rate ,Nomograms ,medicine.anatomical_structure ,Cohort ,Prostatic Neoplasm ,Neoplasm Grading ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies ,Human - Abstract
Background Early salvage radiotherapy (eSRT) represents the only curative option for prostate cancer patients experiencing biochemical recurrence (BCR) for local recurrence after radical prostatectomy (RP). Objective To develop and internally validate a novel nomogram predicting BCR after eSRT in patients treated with RP. Design, setting, and participants Using a multi-institutional cohort, 472 node-negative patients who experienced BCR after RP were identified. All patients received eSRT, defined as local radiation to the prostate and seminal vesicle bed, delivered at prostate-specific antigen (PSA) â¤0.5 ng/ml. Outcome measurement and statistical analysis BCR after eSRT was defined as two consecutive PSA values â¥0.2 ng/ml. Uni- and multivariable Cox regression models predicting BCR after eSRT were fitted. Regression-based coefficients were used to develop a nomogram predicting the risk of 5-yr BCR after eSRT. The discrimination of the nomogram was quantified with the Harrell concordance index and the calibration plot method. Two hundred bootstrap resamples were used for internal validation. Results and limitations Mean follow-up was 58 mo (median: 48 mo). Overall, 5-yr BCR-free survival rate after eSRT was 73.4%. In univariable analyses, pathologic stage, Gleason score, and positive surgical margins were associated with the risk of BCR after eSRT (all p ⤠0.04). These results were confirmed in multivariable analysis, where all the previously mentioned covariates as well as pre-RT PSA were significantly associated with BCR after eSRT (all p ⤠0.04). A coefficient-based nomogram demonstrated a bootstrap-corrected discrimination of 0.74. Our study is limited by its retrospective nature and use of BCR as an end point. Conclusions eSRT leads to excellent cancer control in patients with BCR for presumed local failure after RP. We developed the first nomogram to predict outcome after eSRT. Our model facilitates risk stratification and patient counselling regarding the use of secondary therapy for individuals experiencing BCR after RP. Patient summary Salvage radiotherapy leads to optimal cancer control in patients who experience recurrence after radical prostatectomy. We developed a novel tool to identify the best candidates for salvage treatment and to allow selection of patients to be considered for additional forms of therapy. © 2013 European Association of Urology.
- Published
- 2014
15. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies
- Author
-
Thomas Wiegel, Alberto Briganti, Karin Haustermans, Hein Van Poppel, Pierre I. Karakiewicz, Giorgio Gandaglia, Bertrand Tombal, Wolfgang Hinkelbein, Francesco Montorsi, Shahrokh F. Shariat, Steven Joniau, Maxine Sun, Cesare Cozzarini, Briganti, A, Joniau, S, Gandaglia, G, Cozzarini, C, Sun, M, Tombal, B, Haustermans, K, Hinkelbein, W, Shariat, Sf, Karakiewicz, Pi, Montorsi, Francesco, Van Poppel, H, and Wiegel, T.
- Subjects
Oncology ,Male ,Radiology, Nuclear Medicine and Imaging ,Cancer Research ,Time Factors ,Neoplasm, Residual ,medicine.medical_treatment ,urologic and male genital diseases ,Prostate cancer ,Retrospective Studie ,Medicine ,Radiation ,Prostatectomy ,Medicine (all) ,Middle Aged ,Survival Rate ,Regression Analysis ,Adjuvant ,Human ,Biochemical recurrence ,medicine.medical_specialty ,Time Factor ,Pelvi ,Regression Analysi ,Pelvis ,Internal medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Survival rate ,Proportional Hazards Models ,Retrospective Studies ,Aged ,business.industry ,Proportional hazards model ,Prostatic Neoplasms ,Retrospective cohort study ,Prostate-Specific Antigen ,medicine.disease ,Surgery ,Radiation therapy ,Prostatic Neoplasm ,Proportional Hazards Model ,Lymph Node Excision ,Radiotherapy, Adjuvant ,Neoplasm Grading ,Neoplasm Recurrence, Local ,business - Abstract
Purpose: The aim of our study was to evaluate patterns and predictors of early biochemical recurrence (eBCR) after radical prostatectomy (RP) and adjuvant radiation therapy (aRT) in order to identify which individuals might benefit from additional treatments. Methods and Materials: We evaluated 390 patients with pT(3)N(0) prostate cancer (PCa) receiving RP and aRT at 6 European centers between 1993 and 2006. Patients who were free from BCR at 0.2 ng/mL within 2 or 3 years after aRT. Uni- and multivariable Cox regression analyses predicting overall and eBCR after aRT were fitted. Covariates consisted of preoperative PSA results, surgical margins, pathological stage, Gleason score, and aRT dose. Results: Overall, 5- and 8-year BCR-free survival rates were 77.1% and 70.8%, respectively. At a median follow-up of 86 months after aRT, 33 (8.8%) and 55 (14.6%) men experienced BCR within 2 or 3 years after aRT, respectively. In multivariable analyses, Gleason scores of 8 to 10 represented the only independent predictor of eBCR after aRT (all, P =.3). Conclusions: High Gleason score represents the only predictor of eBCR after RP and aRT in patients affected by pT(3)N(0) PCa. Given the association between early PSA recurrence, clinical progression, and mortality, these patients might be considered candidates for adjuvant medical therapy and/or prophylactic whole-pelvis radiation therapy in addition to aRT, delivered to the prostatic bed. (C) 2013 Elsevier Inc.
- Published
- 2013
16. Fractionated irradiation can induce functionally relevant multidrug resistance gene and protein expression in human tumor cell lines.
- Author
-
Bottke D, Koychev D, Busse A, Heufelder K, Wiegel T, Thiel E, Hinkelbein W, and Keilholz U
- Subjects
- Antineoplastic Agents pharmacology, Cell Line, Tumor, Cell Survival drug effects, Cell Survival radiation effects, Humans, RNA, Messenger genetics, RNA, Messenger metabolism, Sensitivity and Specificity, ATP Binding Cassette Transporter, Subfamily B, Member 1 genetics, Gene Expression Regulation radiation effects, Multidrug Resistance-Associated Proteins genetics, Neoplasms genetics, Neoplasms metabolism, Vault Ribonucleoprotein Particles genetics
- Abstract
The molecular basis of radiotherapy-related multidrug resistance (MDR) is still unclear. Here we report on a study investigating the effect of fractionated irradiation on expression of the MDR-associated proteins P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), and lung resistance-related protein (LRP), the respective mRNAs, and the functional consequences. Cells of six colon and five breast cancer cell lines were irradiated with a total dose of 27 Gy, five fractions of 1.8 Gy per week. The mRNA expression was measured by quantitative RT-PCR, protein levels and drug sensitivity to cisplatin, doxorubicin and bendamustine were assessed by flow cytometry. Breast cancer cell lines showed enhancement of the mRNAs encoding for P-gp, MRP1 and LRP in comparison to nonirradiated cells. No up-regulation of the three mRNA species was observed in the colon cancer cell lines. After irradiation, three breast cancer cell lines showed an up-regulation of LRP, one line an up-regulation of MRP1, and four lines a small up-regulation of P-gp. In the colon cancer cell lines, radiation induced significant enhancement of all three proteins. In comparison to controls, the irradiated cells lines showed a significant resistance to cisplatin, doxorubicin and bendamustine. This study confirms the prior reports of enhancement of P-gp and MRP1 after irradiation, which is accompanied by a multidrug resistance phenomenon, but in addition proposes a novel mechanism in the appearance of MDR after radiation-induced enhancement of LRP.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.